Zoster-immune globulin

Zoster-immune globulin (ZIG) is a pharmaceutical product derived from the plasma of individuals with high levels of antibody to the varicella-zoster virus. It is used to provide passive immunity to individuals who have been exposed to the varicella-zoster virus, but who have not yet developed immunity to the virus.

History

Zoster-immune globulin was first developed in the 1970s as a means of providing passive immunity to individuals exposed to the varicella-zoster virus. It was initially used in hospital settings to protect healthcare workers and patients who were at high risk of severe disease if they contracted the virus.

Production

Zoster-immune globulin is produced by collecting plasma from individuals with high levels of antibody to the varicella-zoster virus. The plasma is then processed to extract the antibodies, which are then purified and concentrated to produce the final product.

Use

Zoster-immune globulin is used to provide passive immunity to individuals who have been exposed to the varicella-zoster virus, but who have not yet developed immunity to the virus. This includes individuals who are at high risk of severe disease if they contract the virus, such as those with weakened immune systems, pregnant women, and newborns whose mothers contracted varicella shortly before delivery.

Side Effects

As with any pharmaceutical product, Zoster-immune globulin can have side effects. These can include fever, rash, and pain at the injection site. In rare cases, more serious side effects such as anaphylaxis can occur.

See Also

• Varicella-zoster virus
• Immune globulin
• Passive immunity

References

‎